We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/11/2015 09:44 | There's a new Interview with Graham Lumsden on Directors talk, see link below:: Graham Lumsden chats to DirectorsTalk about the Phase III Clinical Trials 80mg fixed dose. Graham explains why a fixed dose is important, how this benefits the company, patients and clients and how the 80mg dose was determined. | timbo003 | |
24/11/2015 08:45 | Another positive RNS....but will we finish RED. | regandharry5 | |
24/11/2015 07:56 | AH. R eceipt of FDA Concurrence with Optimized Dose for Iclaprim Phase III Clinical Trials. | hazl | |
11/11/2015 12:54 | Another positive RNS but will we finish red...Don't you just love these MMs. | regandharry5 | |
11/11/2015 08:54 | Northlands have reiterated fair value of 114p,Its closest peer Nasdaq listed Paratek trades at a substantial premium to northlands target price for motif,if approved could achieve a $1billion a year in sales. | victor2 | |
11/11/2015 08:10 | everything's quietly happening in the background......... | hazl | |
11/11/2015 08:01 | I see they are going for the centralized procedure in Europe, excellent! | timbo003 | |
11/11/2015 07:50 | Steady progress through the regulatory maze ..... | small crow | |
27/10/2015 07:55 | Ah! Selected to present at Bio-Europe. | hazl | |
17/10/2015 16:44 | Thanks Proactive, link to video now in the header It was a bit of a left field question at the end I thought! | timbo003 | |
16/10/2015 14:48 | Video interview with CEO Lumsden Graham Lumsden, chief executive at Motif Bio (LON:MTFB), says the tie-up with contract research organisation Covance is critical in de-risking the final stage clinical trials of Motif’s flagship drug iclaprim. Covance will run two phase-III studies on iclaprim to assess whether it is better than existing treatments for tackling bacteria that are resistant to traditional antibiotics. Motif aims to market iclaprim in 2018 and Lumsden says there will be 10 years of market exclusivity meaning no generic competition until at least 2028. He anticipates a similar protection period in Europe. | proactivest | |
16/10/2015 09:02 | yes you can feel the momentum building imo | hazl | |
16/10/2015 06:18 | Excellent partner announced this am. | small crow | |
13/10/2015 09:08 | Don't like the sound of 'infectious diseases week'! Seriously,though,its going in the right direction here. IMO | hazl | |
13/10/2015 06:34 | This is looking poised for further gains | gersemi | |
05/10/2015 16:06 | Directors buy...60K worth. Shows confidence. | regandharry5 | |
30/9/2015 09:07 | There's some new Broker comment (Beaufort) published this morning on the proactive web site: | timbo003 | |
29/9/2015 08:38 | Hilarys tweet about the pharma sector,in general has not helped us,I'm afraid. Will retain a small holding. | hazl | |
28/9/2015 13:01 | Thanks very much indeed timbo | hazl | |
28/9/2015 12:27 | See below a few supplementary notes on Graham Lumsden’s presentation at the proactiveinvestors meeting last Thursday: During the presentation GL made several references to Motif’s market cap vs comparable companies in the US and said it was the director’s objective to close the valuation gap (possibly with a Nasdaq listing). He cited Paratek a couple of times as a good example of the valuation gap. Paratek is a Nasdaq listed small pharma specialising in antibiotics with one just main clinical asset (Omadacyclin) which is currently in phase III studies and running about 1 year ahead of Motif’s Iclaprim. Paratek’s market cap is around $400m compared to Motif’s market cap of around $115m (or $150m fully diluted) The other comparitors mentioned were Durata, Cempra and Tetraphase He emphasised that Motif need around £35m for the phase III clinicals and they already have £25m and added that the additional funding could come from various sources, he spent time discussing two such routes: 1) an equity raise (at the right price) and I assume they have a Nasdaq listing in mind for this option. 2) up-front fee from a partnership for a particular geographical region (not the US), with a regional deal for a drug of Ipraclim’s potential normally commanding an upfront fee of around 10 – 15m. Motif had discussions concerning the phase III clinicals for Iclaprim with the Netherlands regulators last week (the Netherlands are presumably the rapporteurs for Europe submission) and have agreement on the proposed clinical trial program. Motif will be granted 10 years exclusivity on the regulatory data within Europe (which is basically as good as having 10 years extra patent life). When GL talked about Iclaprim’s mechanism of action, he placed particular emphasis on its unusually good tissue penetration and the fact that unlike most other antibiotics there was no need to adjust the dose when there were other co-morbidities accompanying bacterial infection, which is one of the reasons why an oral dosage form for Iclaprim would be particularly useful. GL spent some time discussing the near term pipeline. One project they are particularly keen to progress is to develop an orally administered dosage form for Iclaprim. This would be particularly useful where prolonged antibiotic dosing is required and especially for indications where deep tissue penetration is desirable. Graham cited Osteomylitis as a target indication for oral iclaprim: Osteomyelitis requires antibiotic dosing over a period of 6 weeks (too long a period for IV administration) and iclaprim shows particularly good penetration into bone tissue compared to many other antibiotics (Note it also shows exceptional penetration into lung tissue hence its use in HABP) . Oral Iclaprim may only require one phase II study in Osteoyelitis for approval, assuming the phase III program on the iv formulation for HABP and ASSSI has been successful. GL mentioned 4 other in licencing pipeline opportunities (see slide 19), but singled out one of them that was of particular interest as it would complement Iclaprim for the treatment of HABP (which can be caused my multiple different pathogens) he opined that this particular candidate may get initial approval with minimal clinical data (phase II studies). I spoke to GL after the meeting and introduced myself as one of the fortunate few who had managed to buy a few shares in the IPO, adding that I had since topped up in my SIPP (at around 50p). He congratulated me on getting some in the IPO, I asked why so few shares were issued at the IPO and why the price was so low. He said that the main objective of the IPO was to get a listing (raising substantial funds seems to be a secondary objective). If they had not got a listing when they did, they would have lost Iclaprim, so it was essential to get the IPO away extremely quickly and at short notice. That certainly reflects my own experience, the only information I received on Motif was a slide set on Feb 26th lunchtime, I then had to make a decision on whether to apply on the same day and have funds available on account in order to proceed. | timbo003 | |
25/9/2015 11:18 | It was a good meeting last night and there is a new interview with Graham Lumsden over on the Proactive Website along with the slide set from last nights presentation I will add a few additional thoughts later but have an AGM write up (SDI) from earlier this week to do first. | timbo003 | |
24/9/2015 10:32 | I'll be going along tonight, anyone else planning to attend? | timbo003 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions